VEGFA and Miyoshi myopathy: Elevated levels of circulating and serousal VEGF in MM patients and the expression of VEGF and VEGFR on MM cells that can drive their proliferation and enhance their survival [9] has led to the evaluation of VEGFR targeted therapies.